THE ADMINISTRATION OF TRANS-RESVERATROL AT DOSES OF 1 AND 3 MG/KG REVERSES THE POSTURAL IMBALANCE IN HEMIPARKINSONIAN RATS WITH A BENEFICIAL POST-TREATMENT EFFECT
THE ADMINISTRATION OF TRANS-RESVERATROL AT DOSES OF 1 AND 3 MG/KG REVERSES THE POSTURAL IMBALANCE IN HEMIPARKINSONIAN RATS WITH A BENEFICIAL POST-TREATMENT EFFECT
-
DOI: https://doi.org/10.22533/at.ed.1594242423024
-
Palavras-chave: Ajuste de pasos. Inestabilidad postural. Hemiparkinsonismo. Neuroprotección. Trans-resveratrol
-
Keywords: Step adjustment. Postural instability. Hemiparkinsonism. Neuroprotection. Trans-resveratrol.
-
Abstract:
Parkinson's disease is chronic and causes a postural imbalance that affects the gait and balance of patients. There is progressive loss of nigro-striatal dopaminergic neurons. It generates a high economic cost and current therapies produce unwanted effects. The objective of the present work was to evaluate the beneficial effect on postural adjustment with the systemic administration of trans-resveratrol at doses of 1 and 3 mg/kg in rats with hemiparkinsonism induced with 6-OHDA. The 14 rats used showed a significant reduction in steps with the contralateral paw (PC) without involvement of the ipsilateral paw (PI) post-injury. The vehicle did not produce reversal of motor impairment, but there was deterioration in the ipsilateral paw during washing. The motor impairment produced by 6-OHDA was reversed, both in the CP and the IP with the administration for 3 weeks of trans-resveratrol at 1 and 3 mg/kg, significantly reducing the asymmetry between both legs, without presenting development of effects. collaterals. The motor improvement produced by trans-resveratrol was maintained up to 6 months after stopping the treatment of both doses of 1 and 3 mg/kg, although at the dose of 1 mg/kg the improvement had some fluctuations.
The above suggests that trans-resveratrol is effective in reversing postural imbalance without causing side effects and that this effect can last for a long time after stopping treatment, suggesting that it could be a safe therapy with a prolonged effect in patients with PD.
- Carlos Enrique Perez-Osorio
- José L. Bata-García
- Gilda C. Solís-Uicab
- Jorge J. Alcocer-Sosa
- Karen C. Hernández-Monsrreal